Abstract
The serum levels of the low molecular form of insulin-like growth factor binding protein (IGFBP) was determined in 56 outpatients with diabetes mellitus by a radioimmunoassay developed for amniotic 35 kDa IGFBP. The mean level of 35 kDa IGFBP was found to be threefold higher in insulin dependent diabetes mellitus (IDDM), 112 ± 13 ng/ml, than in age matched controls, 37 ± 2 ng/ml, while the mean level in non-insulin dependent diabetes mellitus (NIDDM), 16 ± 2 ng/ml, was decreased. In hospitalized IDDM patients there was a significant correlation (r = 0.91, p< 0.01) between fasting blood-glucose and 35 kDa IGFBP levels, not found in NIDDM patients. During insulin infusion the 35 kDa IGFBP levels declined with a half-life of 60–120 min. The decline in IGFBP continued even after the establishment of steady state B-glucose at 4.7 mmol/l. In conclusion, the elevated 35 kDa IGFBP levels in IDDM can be attributed to insulin deficiency and may reflect a reduced bioavailability of the IGFs at the target cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hall K., Brandt J., Enberg G., Fryklund L. Immunoreactive somatomedin A in human serum. J. Clin. Endocrinol. Metab. 48: 271, 1979.
Furlanetto R.W. The somatomedin C binding protein: Evidence for a heterologous subunit structure. J. Clin. Endocrinol. Metab. 51: 12, 1980.
Martin J.L., Baxter R.C. Antibody against acid-stable insulinlike growth factor binding protein detects 150000 mol WT growth hormone dependent complex in human plasma. J. Clin. Endocrinol. Metab. 61: 799, 1985.
Nissley S.P., Rechler M.M. Insulin-like growth factors: Biosynthesis, receptors, and carrier proteins. In: Li C.H. (Ed.), Hormonal proteins and peptides. Academic Press, Orlando, 1984, vol. 12, p. 127.
Chochinow R.H., Mariz I.K., Hajek AS., Daughaday W.H. Characterization of a protein in mid-term human amniotic fluid which crossreacts in the somatomedin C radioreceptors assay. J. Clin. Endocrinol. Metab. 44: 902, 1977.
Povoa G., Enberg G., Jörnvall H. Hall K. Isolation and characterization of a somatomedin binding protein from midterm human amniotic fluid. Eur. J. Biochem. 144: 199, 1984.
Povoa G., Roovete A., Hall K. Cross-reaction of serum somatomedin-binding protein isolated from human amniotic fluid in a radioimmunoassay developed for somatomedin-binding protein. Acta Endocrinol. (Kbh.), 107: 563, 1984.
Koistinen R., Kalkkinen N., Huhtala M.L., Seppälä M., Bohn H., Rutanen E.M. Placental protein 12 is a decidual protein that binds somatomedin and has an identical N-terminal amino acid sequence with somatomedin-binding protein from human amniotic fluid. Endocrinology 118: 1375, 1986.
Hall K., Hansson U., Lundin G., Luthman M., Persson B., Povoa G., Stangenberg M., Ofverholm U. Serum levels of somatomedin and somatomedin-binding protein in pregnant women with type I or gestational diabetes and their infants. J. Clin. Endocrinol. Metab. 63: 1300, 1979.
Baxter R.G., Cowell C.T. Diurnal rhythm of growth hormone — independent binding protein for insulin-like growth factors in human plasma. J. Clin. Endocrinol. Metab. 65, 432, 1987.
Povoa G., Isaksson M., Jörnvall H., Hall K. The somatomedin-binding protein isolated from a human hepatoma cell line is identical to the human amniotic fluid somatomedin-binding protein. Biochem. Biophys. Res. Commun. 128: 1071, 1985.
Povoa G. Somatomedin-binding protein. Isolation, determination, and studies of its regulation. Thesis 1986. ISBN 91 -7900-001 -0, Karolinska Institute.
Hall K., Brismar K., Povoa G. The role of somatomedin binding protein. In: Isaksson O., Binder C., Hall K., Hokfelt B. (Eds.), Growth hormone: Basic and clinical aspects. International Congress Series 748, Excerpta Medica, Elsevier, Amsterdam, 1987 p. 415.
Albertsson-Wikland K., Rosberg S., Hall K. Spontaneous secretion of growth hormone and serum levels of insulin like growth factor I and somatomedin binding protein in children of different growth rates. In: Isaksson O., Binder C., Hall K., Hokfelt B. (Eds.), Growth hormone: Basic and clinical aspects. International Congress Series 748 Excerpta Medica, Elsevier, Amsterdam 1987, p. 163.
Drop S.L.S., Valiquette G., Guyda K.J., Corvol N.T., Posner B.I. Partial purification and characterization of a binding protein for insulin-like activity (ILAs) in human amniotic fluid: a possible inhibitor of insulin-like activity. Acta Endocrinol. (Kbh.) 90: 505, 1979.
Elgin R.G., Busby W.H., Jr., Clemmons D.R. An insulin-like growth factor (IGF) binding protein enhances the biological response to IGF-I. Proc. Natl. Acad. Sci. USA. 84: 3254, 1987.
Banskota N.K., Carpentier J.L., King G.L. Processing and release of insulin and insulin-like growth factor I by macro- and microvascular endothelial cells. Endocrinology 119: 1904, 1986.
Hachiya H.L., Carpentier J.L., King G.L. Comparative studies on insulin-like growth factor II and insulin processing by vascular endothelial cells. Diabetes 35, 1065, 1986.
Suikkari A.-M., Koivisto V.A., Rutanen E.M. Yki-Järvinen H. Karonen S.L., Seppälä M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J. Clin. Endocrinol. Metab. 66: 266, 1988.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brismar, K., Gutniak, M., Povoa, G. et al. Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. J Endocrinol Invest 11, 599–602 (1988). https://doi.org/10.1007/BF03350189
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350189